Flumatinib Therapeutic Drug Monitoring Reveals Key Exposure Thresholds for Molecular Response in Chinese CML-CP Patients
Key Insights
A single-center study of 110 Chinese CML-CP patients found flumatinib Cmax_2h significantly associated with both MMR (p<0.001) and DMR (p<0.001), while Cmin showed no significant correlation.
ROC analysis identified a Cmax_2h threshold of >87.75 ng/mL for MMR (AUC=0.87, sensitivity 77.4%, specificity 86.7%) and >132.0 ng/mL for DMR (AUC=0.79, sensitivity 51.4%, specificity 93.5%).
Gastrointestinal adverse events correlated with higher flumatinib exposure: diarrhea with Cmin >49.0 ng/mL and nausea/vomiting with Cmax_2h >126.5 ng/mL.
A new study from Chinese researchers has established the first quantitative exposure-response-toxicity relationships for flumatinib, a second-generation BCR::ABL1 (search) tyrosine kinase inhibitor (TKI) independently developed in China, in patients with chronic-phase chronic myeloid leukemia (search) (CML-CP). The findings, published in Drug Design, Development and Therapy, identify preliminary plasma concentration thresholds that may eventually inform therapeutic drug monitoring (TDM) strategies for personalized CML management.
The single-center study enrolled 110 CML-CP patients at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2020 and December 2024. All patients received flumatinib at a standard oral daily dose of 600 mg, with dose reductions to 400 mg or 200 mg implemented after achieving deep molecular response (DMR). Flumatinib was administered as first-line therapy in 68 patients (61.8%), second-line in 26 (23.6%), and third-line or above in 16 (14.5%).
Flumatinib Exposure Demonstrates Dose-Dependent Pharmacokinetics
Therapeutic drug monitoring revealed clear dose proportionality across the three dose levels. Mean Cmin values increased with ascending dose: 12.64 ± 8.28 ng/mL at 200 mg, 28.10 ± 18.67 ng/mL at 400 mg, and 44.61 ± 29.22 ng/mL at 600 mg daily (p<0.001). Similarly, mean Cmax_2h rose from 35.33 ± 10.11 ng/mL at 200 mg to 73.83 ± 35.64 ng/mL at 400 mg and 113.31 ± 65.47 ng/mL at 600 mg (p<0.001). These concentrations were comparable to those previously reported by Jiang et al, who found steady-state Cmax of 129.0 ± 75.8 ng/mL and Cmin of 33.1 ± 14.3 ng/mL for the 600 mg daily dosage.
Cmax_2h Emerges as Key Predictor of Molecular Response
Among first-line patients, those achieving major molecular response (MMR, defined as BCR::ABL1 (search)^IS ≤ 0.1%) exhibited significantly higher Cmax_2h than non-responders (127.75 ± 60.40 vs. 58.29 ± 30.47 ng/mL; p<0.001). Similarly, DMR responders (BCR::ABL1^IS ≤ 0.01%) showed higher Cmax_2h than non-DMR patients (134.63 ± 66.45 vs. 88.87 ± 47.89 ng/mL; p<0.001). Notably, no significant differences were observed in Cmin between responders and non-responders for either endpoint.
Multivariable logistic regression analysis confirmed that Cmax_2h remained a significant independent predictor of both MMR (OR=0.971, p=0.022) and DMR (OR=0.981, p=0.010) after adjusting for age, sex, and flumatinib therapy duration.
Receiver operating characteristic (ROC) analysis identified an optimal Cmax_2h threshold of >87.75 ng/mL for MMR (AUC=0.87, 95% CI: 0.78–0.96; sensitivity 77.4%, specificity 86.7%) and >132.0 ng/mL for DMR (AUC=0.79, 95% CI: 0.68–0.89; sensitivity 51.4%, specificity 93.5%). Patients exceeding these thresholds demonstrated significantly higher cumulative incidence of both MMR (p=0.002) and DMR (p<0.001).
"The observation that Cmax_2h was significantly associated with both MMR and DMR, whereas Cmin did not reach statistical significance in this cohort, suggests that Cmax_2h may be a more informative predictor of molecular response than trough exposure for flumatinib," the authors noted, while cautioning that intensive pharmacokinetic profiling would be required to definitively characterize these relationships.
Higher Exposure Targets May Be Needed in Later-Line Therapy
Among 42 patients receiving later-line flumatinib therapy, the effective treatment group achieved substantially higher mean Cmax_2h than the treatment failure group (133.75 ± 39.02 vs. 88.69 ± 65.07 ng/mL; p=0.003). The concentration distributions in the effective later-line group appeared to shift toward higher values compared to first-line settings, raising the hypothesis that higher exposure targets may be needed in later-line therapy for patients with elevated tumor burden and complex prior TKI exposure histories.
Gastrointestinal Toxicity Correlates with Elevated Flumatinib Concentrations
The most common adverse events were diarrhea (36.4%), hyperuricemia (20.0%), thrombocytopenia (18.2%), and hepatobiliary dysfunction (15.5%). Patients experiencing diarrhea demonstrated significantly higher concentrations than unaffected individuals (Cmax_2h: 136.28 ± 75.09 vs. 99.39 ± 54.94 ng/mL; p=0.006; Cmin: 56.07 ± 36.10 vs. 37.66 ± 21.63 ng/mL; p=0.002). Those with nausea and vomiting also showed elevated Cmax_2h (151.05 ± 68.81 vs. 108.49 ± 63.81 ng/mL; p=0.016).
ROC analysis confirmed discriminatory capacity: for diarrhea, a Cmin >49.0 ng/mL yielded AUC=0.68 (95% CI: 0.58–0.79), sensitivity 62.5%, and specificity 74.2%; for nausea/vomiting, Cmax_2h >126.5 ng/mL achieved AUC=0.72 (95% CI: 0.56–0.87), sensitivity 75.0%, and specificity 70.2%.
Age-Dependent Pharmacokinetics and Dose Reduction Outcomes
Flumatinib concentrations demonstrated an age-dependent relationship, with Cmin increasing progressively with advancing age (p=0.008): 30.96 ± 16.90 ng/mL in patients under 35 years, 46.07 ± 20.81 ng/mL in those aged 35–56, and 56.18 ± 43.74 ng/mL in patients over 56. Elderly patients exhibited greater inter-individual variability, particularly in Cmin.
Among 36 patients who achieved DMR before dose reduction, those who maintained MMR after reduction had significantly higher Cmax_2h at the time of reduction compared to those who subsequently lost MMR (77.03 ± 34.35 vs. 25.80 ± 15.27 ng/mL; p=0.024). Similarly, patients maintaining DMR had higher Cmax_2h than those who lost DMR (79.94 ± 33.63 vs. 31.05 ± 12.54 ng/mL; p=0.002).
Study Limitations and Future Directions
The authors emphasized several important limitations, including the single-center retrospective design, limited sample size, sparse pharmacokinetic sampling, and lack of independent validation for the proposed thresholds. "These findings are hypothesis-generating rather than definitive," they stated, calling for "prospective studies with larger cohorts, standardized TDM protocols, and dose-adjusted analyses to validate the exposure thresholds and clarify their impact on long-term clinical outcomes."
If validated, the exploratory findings could potentially inform clinical management: patients not achieving MMR on standard 600 mg dosing with Cmax_2h ≤87.75 ng/mL might be candidates for dose escalation studies, while those with Cmax_2h exceeding 132 ng/mL who fail to attain DMR could be prioritized for adherence assessments, drug-drug interaction screening, and BCR::ABL1 (search) kinase domain mutation testing.